Construction has started on the HDR-designed RNA Research and Pilot Manufacturing Facility co-located at Macquarie University’s Wallumattagal campus.
Once established, the facility will be used to manufacture vaccines and treatments for human and animal clinical trials, as well as undertake research studies. It will also be a space for housing and testing RNA technology, which has the potential to assist with the prevention and treatment of a broad spectrum of health concerns, such as viruses and genetic diseases.
The new facility – located in North Ryde – will be connected to the Connect Macquarie Park Innovation District, a hub containing several medical and health-related organisations, as well as industrial and technology startups.
Macquarie University’s deputy vice-chancellor of research, Professor Sakkie Pretorius, said that the new facility is a “significant addition to the thriving medical precinct within the Connect Macquarie Park Innovation District.”
“RNA research has incredible potential, and we share in RNA Australia’s vision for advancing biomedical science for the benefit of Australia and the world,” Pretorius added.
Imagined as a “pavilion in the trees,” the contextual facade adopts a colour palette that references surrounding native trees. Additionally, vertical elements have been incorporated on the exterior to mimic tree forms in a nearby forest.
The project is targeting a 5-star Green Star Buildings rating.
Construction of the RNA Research and Pilot Manufacturing Facility is expected to be completed in 2026. A state significant development application was lodged for the project in late 2023.
Source: Architecture - architectureau
